摘要
恶性肿瘤是全球重大公共卫生挑战,筛查是降低其死亡率的关键手段。然而,目前仅少数癌种有适宜的筛查方法,且传统单癌筛查方法存在侵入性强、准确性低、依从性差等弊端。基于液体活检技术的多癌种早期检测(MCED),通过检测血液等体液中的细胞游离DNA、细胞游离RNA、蛋白质和代谢物等标志物,实现了无创、高效的多癌种联合早期检测,显著拓展了可筛查癌种范围及筛查人群覆盖率,展现出改善当前癌症筛查策略的巨大潜力。基于液体活检技术多癌种联合筛查专家共识(2025版)系统梳理了基于液体活检技术的MCED进展、标志物选择与检测技术、癌种选择、研究设计与临床效用评估以及实施路径等内容,旨在为MCED的深入研究与广泛应用提供科学指导,推动恶性肿瘤筛查策略的持续优化。
Cancer stands as a significant global public health challenge,and cancer screening serves as a pivotal strategy for reducing its mortality.Presently,only a limited number of cancer types have appropriate screening methods available.Traditional single-cancer screening approaches are fraught with limitations,including invasiveness,low accuracy,and poor patient compliance.Multi-cancer early detection(MCED)leveraging liquid biopsy technology enables non-invasive and efficient early detection of multiple cancers by analyzing biomarkers such as cell-free DNA,cell-free RNA,proteins,and metabolites in blood and other bodily fluids.This innovative approach substantially broadens the spectrum of detectable cancers and enhances population coverage,showcasing immense potential for improving existing cancer screening strategies.This expert consensus comprehensively reviews the progress of liquid biopsy-based MCED,biomarker selection and detection technologies, the criteria for cancer type selection,research design and clinical utility evaluation, as well as implementation pathways.The overarching goal of this consensus is to offer scientific guidance for further research and the widespread adoption of MCED,thereby facilitating the continuous optimization of cancer screening strategies.
作者
陈万青
陈可欣
贺宇彤
贾卫华
刘芝华
马红霞
缪小平
潘凯枫
吴晨
夏昌发
邢金良
许永杰
基于液体活检技术的多癌种联合筛查专家共识制定工作组
Wanqing Chen;Kexin Chen;Yutong He;Weihua Jia;Zhihua Liu;Hongxia Ma;Xiaoping Miao;Kaifeng Pan;Chen Wu;Changfa Xia;Jinliang Xing;Yongjie Xu;Working Group for the Development of Expert Consensus on Liquid Biopsy-based Multi-Cancer Early Detection(Office of Cancer Screening,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China;Department of Epidemiology,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin 300060,China;Office of Cancer Prevention,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;State Key Laboratory of Oncology in South China,Guangdong Provincial Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510050,China;Department of Epidemiology,School of Public Health,Nanjing Medical University,Nanjing 211166,China;Department of Epidemiology and Biostatistics,School of Public Health,Wuhan University,Wuhan 430071,China;Department of Epidemiology,Peking University Cancer Hospital&Beijing Institute for Cancer Prevention and Research,State Key Laboratory of Gastrointestinal Cancer Precision Prevention and Integration Therapy,Beijing Key Laboratory of Carcinogenesis and Translational Research,Beijing 100142,China;Department of Physiology and Pathophysiology,School of Basic Medical Sciences,Air Force Medical University,Xi'an 710032,China;不详)
出处
《中国肿瘤临床》
北大核心
2025年第14期727-742,共16页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金项目(编号:82273721)
国家重点研发计划项目(编号:2023YFC2413200)
中国医学科学院医学与健康科技创新工程(编号:2025-I2M-KJ-007)资助。
